Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital
|
|
- Tracy Mosley
- 5 years ago
- Views:
Transcription
1 Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile Janel Liane Cala, RPh Medical Center Hospital
2 Objectives Review pathophysiology, risk factors, prevention, and treatment options of Clostridium difficile Infection (CDI) Introduce Bezlotoxumab (Zinplava) as adjunct treatment for CDI including its indication, dosage, adverse effects Evaluating literature regarding the use of Bezlotoxumab (Zinplava)
3 CLOSTRIDIUM DIFICILE INFECTION Clostridium difficile- gram (+) ; anaerobic; spore forming rod CDI = diarrhea + positive stool sample +/- pseudomembranous colitis* Onset: median of 2-3 days Hx of antimicrobial/antineoplastic tx within 8 wks in a majority of patients Transmission: oral-fecal route; fomites (commodes, rectal thermometer) Watery diarrhea, lower abdominal pain, systemic symptoms (fever, anorexia, nausea, malaise, leukocytosis, CRP, Alb, occult colonic bleeding) Severely ill patients may have little or no diarrhea due to toxic megacolon and paralytic ileus (loss of colonic muscular tone) Cohen, SH et al. (2010). Clinical Practice Guidelines for Clostridium dificile Infection in Adults. Infectious Disease Society of America. Retrieved from
4 CDI: Risk Factors Advanced Age (>/= 65 years) Exposure to antimicrobial agents Cancer chemotherapy Duration of hospitalization Degree of exposure to other patients with CDI Acid- suppressing medications: PPI s, H2RA s Cohen, SH et al. (2010). Clinical Practice Guidelines for Clostridium dificile Infection in Adults. Infectious Disease Society of America. Retrieved from
5
6 Poutanen et al. (2004). Clostridium dificile Associated Diarrhea in Adults. Canadian Medical Association Journal. Retrieved from
7
8 Toxins A and B CDI: Virulence Factors Trigger the attraction and adhesion of PMNs inflammation of the mucosal lining and cellular necrosis, as well as increased peristalsis and capillary permeability, leading to diarrhea and colitis Induce production of TNF-a and proinflammatory IL, contributing to the associated inflammatory response and pseudomembrane formation Toxin B produces more potent damage to colonic mucosa compared to toxin A NAP1/BI/027 Hypervirulent strain has been linked to several outbreaks of severe disease in North America and Europe 16 fold increase in toxin A production and 23 fold increase in toxin B production Poutanen et al. (2004). Clostridium dificile Associated Diarrhea in Adults. Canadian Medical Association Journal. Retrieved from
9 Asymptomatic colonization CDI: Prevalence 7% 26% (adult in acute care facilities) 5% - 7% (elderly in LTCF) Patients who were recently colonized with C. difficile and who have a high serum antibody response to C. difficile toxins were usually protected against diarrhea and remained asymptomatic carriers (Kyne et al, 2001) Clostridium difficile Associated Diarrhea (CDAD) - Accounts for 20% - 30% of antibiotic associated diarrhea - Most commonly recognized cause of infectious diarrhea in healthcare settings - Not a reportable condition- few surveillance data - Incidence rates range from 3.8 to 9.5 cases per patient- days Cohen, SH et al. (2010). Clinical Practice Guidelines for Clostridium dificile Infection in Adults. Infectious Disease Society of America. Retrieved from
10 CDI: Diagnosis Test Sample: diarrheal (unformed) stool, unless (+) ileus Asymptomatic patients- testing not recommended IDSA and SHEA proposed a two-step testing process for CDI: Initial Screen : GDH (Glutamate Dehydrogenase) test GDH - constitutive enzyme produced in large amounts by all strains of CDI Very sensitive, but not very specific for toxigenic C. dificile Detects if C. dificile is present but not if bacteria is producing toxins Confirmatory tests: Cell cytotoxicity test Toxigenic stool culture PCR assays Cohen, SH et al. (2010). Clinical Practice Guidelines for Clostridium dificile Infection in Adults. Infectious Disease Society of America. Retrieved from
11 CDI: Diagnosis CONFIRMATORY TESTS: Cell Cytotoxicity test Tissue culture to detect C. difficile toxin Looks for effects of cytotoxin in human cells time consuming- takes hrs for results excellent specificity; decreased sensitivity Toxigenic Stool Culture Growing C. difficile in culture Excellent specificity & sensitivity; GOLD STANDARD Takes 2-3 days for results Polymerase Chain Reaction (PCR) Rapid, sensitive, expensive Poutanen et al. (2004). Clostridium dificile Associated Diarrhea in Adults. Canadian Medical Association Journal. Retrieved from
12 CDI: Prevention Contact precautions, gloves and gowns Hand washing- antimicrobial soap + water Environmental disinfection- chlorine-containing agents; sporicidal agents Antimicrobial Use: choice, duration, switching IV to PO Decrease (11.5 cases/mo to 3.33 cases/mo) of CDI incidence after decreasing use of Clindamycin (Climo et al) Restrict use of clindamycin and cephalosporins (except for surgical ppx) Probiotics- limited data Cohen, SH et al. (2010). Clinical Practice Guidelines for Clostridium dificile Infection in Adults. Infectious Disease Society of America. Retrieved from
13 CLINICAL DEFINITION SUPPORTIVE CLINICAL DATA RECOMMENDED TREATMENT ADVERSE EFFECTS INITIAL EPISODE (MILD TO MODERATE) INITIAL EPISODE (SEVERE) INITIAL EPISODE (SEVERE, COMPLICATED) WBC <15K SCr < 1.5 x premorbid level WBC >15K SCr > 1.5 x premorbid level Metronidazole 500mg PO TID Vancomycin 125mg PO QID Hypotension, shock, ileus Vancomycin 500mg PO/NGT QID + Metronidazole 500mg IV TID Complete ileus: Vancomycin Retention Enema Vancomycin 500 mg / 100 ml NS Q6H Neurotoxicity- seizures, neuropathy, encephalopathy Metallic Taste Nephrotoxicity Ototoxicity Infusion reaction (Redman Syndrome) Same as initial episode SECOND RECURRENCE Vancomycin tapered/pulsed regimen Cohen, SH et al. (2010). Clinical Practice Guidelines for Clostridium dificile Infection in Adults. Infectious Disease Society of America. Retrieved from
14 ANTIBIOTIC COST PER DOSE REGIMEN COST PER 10 DAY REGIMEN Metronidazole 500 mg $ mg TID $ 22 Vancomycin 125 mg pills $ mg QID $ 680 Vancomycin 125 mg IV (compounded for oral) $ $ mg QID $ $ 400 Fidaxomicin 200 mg $ mg BID $ 2800 Fidaxomycin - binds to and prevents movement of the "switch regions" of bacterial RNA polymerase - recurrent CDAD; failure from Metronidazole/ Vancomycin mg PO BID x 10 days - no renal adjustment needed - high cost - minimal systemic absorption; narrow spectrum of activity - ADV: N/V/ abdominal pain Surawicx, CM et al. (2013). Guidelines for Diagnosis, Treatment, and Prevention of Clostridium dificile Infections. American College of Gastroenterology. Retrieved from
15 CDI: Treatment DC causative antimicrobial ASAP Supportive tx : hydration, correction of electrolyte imbalance Antiperistaltic agents: not recommended; precipitate toxic megacolon Colectomy: for severely ill patients (toxic megacolon) perioperative mortality: Serum lactate >5 mmol/l; WBC ~ st Recurrence: same as initial episode 2nd recurrence: Vanc pulse dosing; avoid metronidazole (cumulative neurotoxicity) Fecal transplant: NGT/ enema; consider after 3 recurrences IVIG: used with success in a small number of patients with fulminant disease Cohen, SH et al. (2010). Clinical Practice Guidelines for Clostridium dificile Infection in Adults. Infectious Disease Society of America. Retrieved from
16 CDI: Recurrence Risk Factors: Age > 65 Increased severity of underlying disease Exposure to additional antibiotics after treatment Compromised immunity; Low serum antibody response to C. dificile toxin Multiple relapses: Rifaximin; Rifampin + Vanc; Rifampin + Colestipol/ Cholestyramine Circulating antitoxin antibodies are protective against primary and recurrent CDI (Leav et al, 2010) Poutanen et al. (2004). Clostridium dificile Associated Diarrhea in Adults. Canadian Medical Association Journal. Retrieved from
17 CDI: Adjunct Treatment
18
19 Fully human IgG that binds to C difficile toxin B Indication: Patients >/= 18 yo receiveing CDI antibacterial therapy Product description: sterile, aqueaous, preservative-free solution Conc: 1000 mg /40 ml Compatible with: NS or D5W (maximum conc of 1 10 mg/ml) Dose: 10 mg/kg IV infusion over 60 minutes (single dose) Use a sterile, nonpyrogenic, low-protein binding micron filter upon administration Storage of diluted solution: Room temp for up to 16 hours (protected from light) Refrigerated (2C to 8C) for up to 24 hours Source: Bezlotoxumab (Zinplava) Prescribing Information- Merck Laboratories
20 Cl = L/day ; Vd = 7.33 L; t1/2 = 19 days Immunogenicity (Healthy subjects and CDI patents) no anti-drug antibody against Zinplava was observed following a single 10mg/kg administration Metabolism: Not metabolized by liver or excreted by kidneys Pharmacokinetics no clinically relevant effects of renal and/or hepatic impairment No dose adjustments are required beyond the weight-based dose Source: Bezlotoxumab (Zinplava) Prescribing Information- Merck Laboratories
21 Bezlotoxumab for Prevention of Recurrent Clostridium dificile infection (MODIFY I and II) Wilcox, MH et al. NEJM 2017; 376: MODIFY: MONOCLONAL ANTIBODIES FOR C. DIFICILE THERAPY
22 Study Design Randomized, double-blind, placebo controlled trials 322 sites, 30 countries from November May 2015 Protocols and amendments were approved by the IRB or independent ethics committee at each study site Inclusion criteria Adults (Age >/= 18) with primary or recurrent CDI Patients receiving SoC antibiotics (10-14 days) Presence of diarrhea + stool test positive for toxigenic C. difficile Patients who have one or more risk factors for recurrent CDI Exclusion Criteria Chronic diarrheal illness, e.g. Ulcerative colitis, Crohns diseas Planned surgery for CDI within 24 hours Positive pregnancy test, Breast-feeding women Patients who received IVIG within 6 months prior to infusion of study drug Patients not expected to survive within 72 hours
23 Methods PARTICIPANTS (2655) Participants recorded unformed BM daily until Day 90 post infusion Safety assessments: Pre & post infusion EKG Monitoring reactions 24hrs after infusion Recording all adverse events through week 12 BEZLOTOXUMAB 10 MG/KG SINGLE DOSE ACTOXUMAB + BEZLOTOXUMAB 10 MG/KG SINGLE DOSE OF EACH PLACEBO 0.9% SALINE ACTOXUMAB 10 MG/KG SINGLE DOSE Actoxumab group was discontinued after MODIFY I: Rate of recurrence was significantly higher in Actoxumab VS Actoxumab + Bezlotoxumab group More deaths and adverse effects (25% sepsis) in Actoxumab VS Placebo
24 Methods BEZLOTOXUMAB (N = 781) PARTICIPANTS (N = 2559) ACTOXUMAB + BEZLOTOXUMAB (N = 773) PLACEBO (N = 773) 2655 participants 2559 were included in the modified intention-to-treat population Most common reasons for discontinuation Death (7%), Withdrawal of consent (4%), Loss to follow up (3%) In 94% of the patients, the study agent was infused within 6 days of initiation of SoC antibiotics Primary Endpoint: proportion of participants with recurrent CDI during 12 weeks of follow up
25
26 The comparison of participants according to hospitalization status, SoC antibiotic therapy, and geographic region, the differences in rates of recurrent infection were consistent with those seen overall. Therefore, choice of SoC antibiotic has no discernible effect on Bezlotoxumab Rate of participants who had recurrent infection was significantly lower in the Bezlotoxumab (17%) and Actoxumab + Bezlotoxumab (15%) VS Placebo (27%) group. Effect of Bezlotoxumab and Actoxumab + Bezlotoxumab on rate of CDI recurrence has no significant difference.
27 Infusion- specific reactions (9%) Nausea (2%), Headache (2%), Dizziness (1%), Fatigue (1%), Pyrexia (1%) 4 weeks post infusion, overall rates of adverse events were similar: Bezlotoxumab (62%), Placebo (61%) Actoxumab- Bezlotoxumab (59%) *** Higher with Actoxumab (67%) CHF exacerbation was reported in CHF patients: Actoxumab- Bezlotoxumab (1%) Bezlotoxumab (2%) Actoxumab (1%), Placebo (2%) No binding or neutralizing antidrug Antibodies to bezlotoxumab were detected
28 Take Home Points Bezlotoxumab is not an antibacterial medication for the treatment of CDI. Bezlotoxumab is a monoclonal antibody indicated for patients >/= 18 yo who are receiving standard of care antibiotic treatment of CDI who are at high risk of recurrence Bezlotoxumab is a single dose, 60- minute infusion that needs to be administered with a micron filter. Bezlotoxumab has the safety profile similar to placebo and does not cause immunogenicity Actoxumab is not efficacious in decreasing rate of CDI recurrence and has no additional benefit when given in combination with Bezlotoxumab. Bezlotoxumab should be used with caution in patients with CHF or other cardiac conditions.
29 Weakness Cost effectiveness of Bezlotoxumab in comparison to other treatment of CDI recurrence (eg FMT, Fidaxomycin) Needs a larger and more diverse study population (in terms of race, pediatric age group, pregnancy, lactating women) Long term safety profile is yet unknown (teratogenicity, carcinogenicity) Efficacy of Bezlotoxumab in combination with treatments other than SoC Antibiotics (FMT) is not studied No further studies were done as to explain why there are higher rates of recurrence and adverse events in Actoxumab group Strengths MODIFY trials included a substantial percentage of participants (77%) who had one or more risk factor for recurrent CDI Although SoC antibiotics are not standardized, study groups were stratified according to SoC antibiotics to make it balanced
30 Conclusions Single IV dose of Bezlotoxumab given with SoC antibiotics provided protection against recurrent CDI for up to 12 weeks that was superior to that provided by SoC antibiotics alone It is proven in decreasing rate of CDI recurrence by 38% lower than that associated with SoC antibiotics alone Safety profile is similar to that of placebo Bezlotoxumab should not be expected to affect initial clinical cure. Efficacy of Bezlotoxumab in recurrent CDI is not affected by the choice of SoC antibiotics Effect on the rate of CDI recurrence were similar with Bezlotoxumab VS Actoxumab + Bezlotoxumab in all subgroups except those infected by strains 027, 078, or 244
31 QUESTIONS
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationClostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
More informationStony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics
Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection
More informationDiagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review
Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated
More informationCDI The Impact. Disclosures. Acknowledgments. Objectives and Agenda. What s in the Name? 11/14/2012. Lets Talk Numbers
Disclosures No conflict of interest to declare Acknowledgments Objectives and Agenda Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Guidelines
More informationUpdates to pharmacological management in the prevention of recurrent Clostridium difficile
Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing
More informationZinplava. (bezlotoxumab) New Product Slideshow
Zinplava (bezlotoxumab) New Product Slideshow Introduction Brand name: Zinplava Generic name: Bezlotoxumab Pharmacological class: Human IgG1 monoclonal antibody Strength and Formulation: 25mg/mL; solution
More informationClostridium difficile Infection: Diagnosis and Management
Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,
More informationLong-Term Care Updates
Long-Term Care Updates April 2017 Bezlotoxumab to Prevent Recurrent Infection By Amy Wilson, PharmD and Zara Risoldi Cochrane, PharmD, MS, FASCP Introduction The Gram-positive bacteria is a common cause
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationCase 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?
Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationCLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System
CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationModern approach to Clostridium Difficile Infection
Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research
More informationClostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate
Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium
More informationACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,
More informationClostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011
Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast
More informationClostridium difficile: Can you smell the new updates?
Clostridium difficile: Can you smell the new updates? Sunish Shah, Pharm.D. PGY-2 Infectious Disease Pharmacy Resident Yale-New Haven Hospital sshah1741@mail.usciences.edu Learning objectives Recognize
More informationClostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018
Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Disclosures None Objectives Highlight important changes in the management of Clostridium difficile
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZINPLAVA safely and effectively. See full prescribing information for ZINPLAVA. ZINPLAVA (bezlotoxumab)
More information! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery
Case MQ is a 44 year old woman that I first saw in Sept 2006 UPDATE ON CLOSTRIDIUM DIFFICILE DISEASE Richard A. Jacobs, M.D.,PhD In MVA in Jan 2003 requiring spinal surgery Subsequently developed fecal
More informationClostridium Difficile Infection in Adults Treatment and Prevention
Clostridium Difficile Infection in Adults Treatment and Prevention Definition: Clostridium Difficile colonizes the human intestinal tract after the normal gut flora has been altered by antibiotic therapy
More informationLong-Term Care Updates
Long-Term Care Updates April 2018 By Austin Smith, PharmD Candidate and Lindsay Slowiczek, PharmD is the most common healthcare-acquired infection (HAI) in the United States. 1,2 A 2014 prevalence survey
More informationUpdate on Clostridium difficile infection.
Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible
More informationDrug Class Update with New Drug Evaluation: Medications for Clostridium difficile Infection
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationA Pharmacist Perspective
Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed
More informationDisclosure. Objectives. Assessment Questions. History. Clinical Case 2/27/2015. Clostridium difficile update and new therapies
Disclosure Clostridium difficile update and new therapies Corey Frederick, PharmD PGY-2 Pharmacy Resident, Infectious Diseases Jackson Memorial Hospital Miami, Florida I do not have a vested interest in
More informationPatient presentation
Update: Clostridium difficile Colitis David H. Kerman, MD Assistant Professor of Clinical Medicine Director, Fellowship Program Division of Gastroenterology University of Miami Miller School of Medicine
More informationNursing Infectious Diseases Topics. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle
Nursing Infectious Diseases Topics David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Clostridium difficile Free Access Via Web Source: Cohen SH,
More informationClostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure
Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Brian S. Zuckerbraun, MD, FACS Henry T. Bahnson Professor of Surgery University of Pittsburgh Chief, Trauma
More informationZinplava Swiss Risk Management Plan Summary V1.5. Swiss Summary of the Risk Management Plan (RMP) for. Zinplava. (Bezlotoxumab 1000mg)
Swiss Summary of the Risk Management Plan (RMP) for (Bezlotoxumab 1000mg) Concentrate for solution for infusion Version 1.5 (November 2016) The Risk Management Plan (RMP) is a comprehensive document submitted
More informationClostridium difficile Infection (CDI) Guideline Update:
Clostridium difficile Infection (CDI) Guideline Update: Understanding the Data Behind the Recommendations Erik R. Dubberke, MD, MSPH A Webinar for HealthTrust Members Professor of Medicine September 24,
More informationThe Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH
The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick
More information9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)
Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In
More informationClostridium difficile Infection (CDI)
18.09.10 월요집담회 Clostridium difficile Infection (CDI) R4 송주혜 Clostridium difficile infection (CDI) Anaerobic gram (+), spore-forming, toxin(tcda&tcdb)-producing bacillus Transmitted among humans through
More informationDISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit
GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationMarch 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments
March 3, 2010 To: Hospitals, Long Term Care Facilities, and Local Health Departments From: NYSDOH Bureau of Healthcare Associated Infections HEALTH ADVISORY: GUIDANCE FOR PREVENTION AND CONTROL OF HEALTHCARE
More informationClostridium difficile
Clostridium difficile Alex Aspinall MD, PhD, FRCPC Clinical Assistant Professor, University of Calgary Division of Gastroenterology and Hepatology, South Health Campus www.seacourses.com 1 Learning Points
More informationClostridium difficile Infection (CDI) Guideline
Clostridium difficile Infection (CDI) Guideline Site Applicability All VCH PHC acute care and residential sites. Practice Level Physicians basic skill Pharmacists basic skill Nurses (RN, LPN, RPN) basic
More informationManagement of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery
Management of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery Rahul Narang, MD Colon and Rectal Surgery Assistant Professor of Surgery No Disclosure Clostridium Difficile Colitis: Treatments,
More informationC. difficile Infection: How it all comes out
C. difficile Infection: How it all comes out Larry Danziger, Pharm.D. Professor of Pharmacy and Medicine College of Pharmacy University of Illinois at Chicago The speaker has no conflicts to disclose.
More informationClostridium difficile Essential information
Clostridium difficile Essential information Clostridium difficile Origins Clostridium difficile (C. diff) is a Gram positive, spore forming, anaerobic bacterium with a rod structure. It was first identified
More informationWhat s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington
What s New for Clostridium difficile 2013 John Lynch MD MPH Harborview Medical Center University of Washington Pathogenic Mechanisms of Diarrhea Toxins: Preformed: S aureus, C perfringens, B cereus Formed
More informationUnderstanding C. diff. atomalliance.org/cdifftraining
Understanding C. diff atomalliance.org/cdifftraining This booklet is a printed guide of the online educational resource atomalliance.org/cdifftraining Target Audience Understanding C. diff This educational
More informationLos Angeles County Department of Public Health: Your Partner in CDI Prevention
Los Angeles County Department of Public Health: Your Partner in CDI Prevention Dawn Terashita, MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health dterashita@ph.lacounty.gov
More informationJourney to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer
Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical
More informationLiterature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLearning Objectives. A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials. Fidaxomicin vs. Vancomycin. Outline 1/3/2012
Learning Objectives A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials Amy E. Lodolce, PharmD, BCPS Assistant Director, Drug Information Group UIC College of Pharmacy Describe the methods and
More informationGUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS
GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS Version 3.0 Date ratified May 2008 Review date May 2010 Ratified by NUH Antibiotic Guidelines Committee NUH Drugs and Therapeutics
More informationClostridium Difficile colitismore
Clostridium Difficile colitismore virulent than ever ECHO- February 18, 2016 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs Hospital Growing problem of pseudomembranous colitis
More informationClostridium difficile infections: Drug treatment re-evaluated
Clostridium difficile infections: Drug treatment re-evaluated Kimberly D. Leuthner, PharmD University Medical Center of Southern Nevada August 11, 2016 Random Fact: The human body has 10 13 human cells
More informationClinical Infectious Diseases IDSA GUIDELINE
Clinical Infectious Diseases IDSA GUIDELINE Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and
More informationFecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond
Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond Amir Patel, MD Assistant Professor of Medicine Froedtert Hospital and the Medical College of Wisconsin I have
More informationdeclara&ons Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD.
Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD. declara&ons No financial disclosures Personal acquaintance, co- worker,
More informationTerapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco
Terapia dell infezione da Clostridium difficile Massimo Coen I Div Mal Inf AO L Sacco Disease Severity Mild CDI 3 5 BM/day WBC 15,000/mm 3 Defining CDI Disease Severity Mild abdominal pain due to CDI Moderate
More informationHEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile
OBJECTIVES HEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile Identify and describe the pathophysiology of C. diff. Identify and describe current therapies in treatment of C. diff Identify
More informationC.Difficile Associated Diarrhea Overview & Management. Sajal Chopra Pharm D. Candidate
C.Difficile Associated Diarrhea Overview & Management Sajal Chopra Pharm D. Candidate Learning Objectives 1. Recognize the increasing incidence of C.difficile associated diarrhea (CDAD) and its risk factors
More informationC. DIFFICILE UPDATE. Heather Bell, DO Infectious Diseases Physician
C. DIFFICILE UPDATE Heather Bell, DO Infectious Diseases Physician None to report DISCLOSURE Case review Review IDSA CDI guidelines discuss changes Questions Testing recommendations Treatment recommendations
More informationEach copy of any part of a JSTOR transmission must contain the same copyright notice that appears on the screen or printed page of such transmission.
Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
More information7/30/2018 C. DIFFICILE UPDATE DISCLOSURE OUTLINE. Heather Bell, DO Infectious Diseases Physician. None to report
C. DIFFICILE UPDATE Heather Bell, DO Infectious Diseases Physician None to report DISCLOSURE Case review Review IDSA CDI guidelines discuss changes Testing recommendations Treatment recommendations Isolation
More informationThe incubation period is unknown. However; the onset of clinical disease is typically 5-10 days after initiation of antimicrobial treatment.
C. DIFFICILE Case definition CONFIRMED CASE A patient is defined as a case if they are one year of age or older AND have one of the following requirements: A laboratory confirmation of a positive toxin
More informationProbiotics for Primary Prevention of Clostridium difficile Infection
Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss
More informationDETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE Policy Number: PDS 021 Effective Date:
More informationDuodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience
Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience Benoit Guery Unité des Maladies Infectieuses CHRU - Faculté de Médecine Lille Conflicts of interest Conferences,
More informationDUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News. Volume 3, Number 6, June 2015
DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News Volume 3, Number 6, June 2015 Diagnostic Testing for Clostridium difficile Infection Background Clostridium difficile
More informationClostridiodes Difficile Colitis: Update on Guidelines. Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018
Clostridiodes Difficile Colitis: Update on Guidelines Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018 Outline Overview of CDI Diagnosis of C Difficile- updates Infection Prevention
More informationManaging Clostridium Difficile: An Old Bug With
932 The Red Section see related editorial on page x Managing Clostridium Difficile: An Old Bug With New Tricks Stephen M. Vindigni, MD, MPH 1,2 and Christina M. Surawicz, MD 1 Am J Gastroenterol (2018)
More informationClostridium difficile
Clostridium difficile Care Homes IPC Study Day Sue Barber Infection Prevention & Control Lead AV & Chiltern CCG s Clostridium difficile A spore forming Bacterium. Difficult to grow in the laboratory hence
More informationLearning Goals. Clostridium difficile. Historical Context. Historical Context 6/27/2012
Learning Goals Clostridium difficile Justin L. Sewell, MD, MPH Assistant Clinical Professor of Medicine University of California San Francisco San Francisco General Hospital Understand the epidemiology,
More information500,000 29,000. New 2015 Data. Lessa et al, N Eng J Med 2015: 34.2% of CDI cases were considered community-acquired
Cost-effective Treatment of Clostridium difficile Infection in the ICU Kevin W. Garey, PharmD, MS. Professor and Chair University of Houston College of Pharmacy New 2015 Data 500,000 29,000 Lessa et al,
More informationClostridium difficile infections and fecal transplant
Objectives Clostridium difficile infections and fecal transplant Recognize patients at risk for C. difficile infection (CDI) Contrast diagnostic testing for CDI Describe treatment strategies for mild,
More informationThe Potential For Microbiome Modification In Critical Illness. Deborah Cook
The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to
More informationSMT19969: A Selective Therapy for C. difficile Infection
SMT19969: A Selective Therapy for C. difficile Infection One Bug, One Drug 25 th September 2012 SMT19969: A Selective Therapy for CDI SMT19969 is a novel antibiotic for the specific treatment of Clostridium
More informationINFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY MAY 2010, VOL. 31, NO. 5
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY MAY 2010, VOL. 31, NO. 5 SHEA-IDSA GUIDELINE Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare
More informationClostridium difficile coli%s. John K. Midturi January 2013
Clostridium difficile coli%s John K. Midturi January 2013 Objec%ves Describe pathogenesis of C. Diff coli%s Review methods of diagnosis of C. Diff coli%s Discuss treatment op%ons first episode refractory
More informationAnnex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening
Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening There s an updated Annex C Annex C is an extension to the PIDAC Infection Prevention
More informationTreatment of Clostridium Difficile Infection in Community Teaching Hospital: A Retrospective Study
International Journal of Infectious Diseases and Therapy 2018; 3(3): 52-61 http://www.sciencepublishinggroup.com/j/ijidt doi: 10.11648/j.ijidt.20180303.12 ISSN: 2578-9651 (Print); ISSN: 2578-966X (Online)
More information-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency
SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,
More informationFecal transplantation as a treatment option for recurrent Clostridium difficile infection
Fecal transplantation as a treatment option for recurrent Clostridium difficile infection Josbert Keller Department of Gastroenterology Haga Teaching Hospital, The Hague Case: 81 yrs, CVA, recurrent UTI,
More informationManagement of the Hospitalized IBD Patient. Drew DuPont MD
Management of the Hospitalized IBD Patient Drew DuPont MD Ulcerative Colitis: Indications for Admission Severe ulcerative colitis Frequent loose bloody stools ( 6 per day) Severe cramps Systemic toxicity:
More informationNote: Active Table of Contents Click to follow link
Clostridium difficile Infection: Prevention, Diagnosis and Treatment Adult/Pediatric Inpatient/Ambulatory/Emergency Department Clinical Practice Guideline Note: Active Table of Contents Click to follow
More informationClostridium difficile
Clostridium difficile Sarah Doernberg, MD, MAS Assistant Professor, University of California, San Francisco Medical Director, Adult Antimicrobial Stewardship Disclosures: Consultant for Actelion, prior
More informationClostridium difficile Update
Clostridium difficile Update Nicholas Havens MD FACP Chief of Medicine Primary Care Harry S Truman Memorial Veterans Hospital Clinical Assistant Professor of Medicine Infectious Diseases University of
More informationC. difficile: The Changing Epidemiology Evaluations Clostridium difficile Thank You to our Sponsors
C. difficile: The Changing Epidemiology Ghinwa Dumyati, MD University of Rochester Monroe County Department of Public Health Thank You to our Sponsors Evaluations School of Public Health, University at
More informationClostridium difficile infection (CDI) Week 52 (Ending 30/12/2017)
Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017) What is Clostridium difficile? Clostridium difficile is a Gram-positive anaerobic spore forming bacillus. It is ubiquitous in nature and
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationCLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT. Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates
CLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates Learning Objectives Recognize patients who are highest risk for C. diff infections
More informationTreatment Update on Fecal Microbiota Transplantation. Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department
Treatment Update on Fecal Microbiota Transplantation Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department Disclosure I serve as a paid medical monitor for Rebiotix Objectives The scope of
More informationOngoing Developments in Management of Clostridium difficile Infection
Ongoing Developments in Management of Clostridium difficile Infection Infectious Diseases Spring Symposium Creighton University School of Medicine April 28, 2018, Omaha, NB Stuart Johnson, MD Loyola U.
More information6/14/2012. Welcome! PRESENTATION OUTLINE CLOSTRIDIUM DIFFICILE PREVENTION. Teaming Up to Prevent Infections! 1) Impact. 2) Testing Recommendations
CLOSTRIDIUM DIFFICILE PREVENTION Beth Goodall, RN, BSN Board Certified in Infection Prevention and Control DCH Health System Epidemiology Director Welcome! Teaming Up to Prevent Infections! CLOSTRIDIUM
More informationEPIDEMIOLOGY AND PREVENTION OF CLOSTRIDIUM DIFFICILE INFECTION (CDI)
EPIDEMIOLOGY AND PREVENTION OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics & Epidemiology Associate Chief Medical Offer, UNC Health Care Medical
More informationAntibiotic Associated Diarrhea (AAD) and Clostridium Difficile Infection (CDI)
Antibiotic Associated Diarrhea (AAD) and Clostridium Difficile Infection (CDI) Dario Conte, M.D. Gastroenterology and Endoscopy Unit Postgraduate School of Gastroenterology Fondazione IRCCS Ca Granda Ospedale
More informationClostridium difficile in Adults
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2018 ~ Resource #340405 Clostridium difficile in Adults Clostridium difficile (C. difficile)
More informationHistorical Perspective
The Diagnosis of C. difficile Infections: Does Molecular Make it More or Less difficile? Stephen M. Brecher Ph.D. VA Boston Health Care System BU School of Medicine The opinions expressed in this presentation
More information